Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ONCE
- CUSIP: N/A
- Web: www.sparktx.com
Capitalization:- Market Cap: $2.26 billion
- Outstanding Shares: 31,128,000
Average Prices:- 50 Day Moving Avg: $60.23
- 200 Day Moving Avg: $58.19
- 52 Week Range: $35.07 - $74.29
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -15.63
- P/E Growth: -0.56
Sales & Book Value:- Annual Revenue: $20.17 million
- Price / Sales: 112.17
- Book Value: $9.32 per share
- Price / Book: 7.80
Profitability:- EBIDTA: ($137,080,000.00)
- Net Margins: -745.48%
- Return on Equity: -44.06%
- Return on Assets: -39.34%
Debt:- Current Ratio: 8.86%
- Quick Ratio: 8.86%
Misc:- Average Volume: 338,449 shs.
- Beta: 3.36
- Short Ratio: 12.48
Frequently Asked Questions for Spark Therapeutics (NASDAQ:ONCE)
What is Spark Therapeutics' stock symbol?
Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."
How were Spark Therapeutics' earnings last quarter?
Spark Therapeutics, Inc. (NASDAQ:ONCE) announced its earnings results on Tuesday, May, 9th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.36) by $0.34. The company had revenue of $1.27 million for the quarter, compared to analysts' expectations of $1.35 million. Spark Therapeutics had a negative net margin of 745.48% and a negative return on equity of 44.06%. The business's quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.95) earnings per share. View Spark Therapeutics' Earnings History.
Where is Spark Therapeutics' stock going? Where will Spark Therapeutics' stock price be in 2017?
10 brokers have issued 12-month target prices for Spark Therapeutics' stock. Their predictions range from $28.00 to $94.00. On average, they anticipate Spark Therapeutics' stock price to reach $71.28 in the next twelve months. View Analyst Ratings for Spark Therapeutics.
What are analysts saying about Spark Therapeutics stock?
Here are some recent quotes from research analysts about Spark Therapeutics stock:
- 1. Chardan Capital analysts commented, "We continue to expect ENDP shares to be range-bound in the near to medium term. Our recent analysis of ENDP’s additional unfunded mesh liability and discussion with a legal expert familiar with mass tort/product liability defense ligation supports our view ENDP will remain highly levered (in the 4s) and the company’s turnaround will take several years. While we view any of our potential settlement scenarios for the company’s additional unfunded mesh liability to be manageable, we believe continued pricing pressure in ENDP’s US generics base business, need for additional advertising and promotion spend to support Xiaflex growth and inability to grow through meaningful acquisitions leave ENDP little room for error." (7/24/2017)
- 2. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (7/19/2017)
- 3. Cantor Fitzgerald analysts commented, "2017 – Year of First Gene Therapy Approval in U.S.? Management reiterated its confidence in filing its rolling BLA in early 2017, and highlighted that the company has completed the necessary manufacturing runs to support its submission. Outstanding items for the filing include finalization of stability testing and CMC module write-up. We believe the timing of the filing could lead to the first approved gene therapy in the U.S. this year and remind investors that the FDA previously amended its granted orphan designation for voretigene neparvovec to cover inherited retinal diseases caused by biallelic RPE65 mutations." (2/23/2017)
- 4. Stifel Nicolaus analysts commented, "Management's 4Q16 earnings announcement/call contained minimally-incremental insight on many of the data catalysts still anticipated for 1H17. We believe management's commentary around the current state of pre-commercialization activities for voretigene neparvovec (VN) ' including directionally positive feedback on both the access and reimbursement fronts ' should ameliorate some of the near-term concerns of those investors anticipating pricing/reimbursement to potentially represent a source of headline risk. We believe anticipation around a number of key near-term data catalysts ' including early-FY17 SPK-7001 data in choroideremia, updated early-April SPK-9001 data in hemophilia B, and preliminary mid-FY17 SPK-8011 data ' should keep ONCE shares at the forefront of relevancy over the coming months. Estimates largely unchanged." (2/23/2017)
Who are some of Spark Therapeutics' key competitors?
Some companies that are related to Spark Therapeutics include Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), China Biologic Products (CBPO), AveXis (AVXS), Prothena Corporation PLC (PRTA), Axovant Sciences (AXON), Sarepta Therapeutics (SRPT), Loxo Oncology (LOXO), Radius Health (RDUS), Aerie Pharmaceuticals (AERI) and Lexicon Pharmaceuticals (LXRX).
Who are Spark Therapeutics' key executives?
Spark Therapeutics' management team includes the folowing people:
- Steven M. Altschuler M.D., Independent Chairman of the Board
- Katherine A. High M.D., President, Chief Scientific Officer, Director
- Jeffrey D. Marrazzo, Chief Executive Officer, Co-Founder, Director
- Stephen W. Webster, Chief Financial Officer
- John Furey, Chief Operating Officer
- Joseph W. La Barge Esq., General Counsel
- Daniel R. Faga, Chief Business Officer
- Lars G. Ekman M.D. Ph.D., Independent Director
- Anand Mehra M.D., Independent Director
- Vincent J. Milano, Independent Director
When did Spark Therapeutics IPO?
(ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.
Who owns Spark Therapeutics stock?
Spark Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include
TYPENEX COMPANY -INVESTMENT, LLC
(9.99%), Sofinnova Management VIII L.L.C. (2.23%), Russell Investments Group Ltd. (0.08%) and Fox Run Management L.L.C. (0.03%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Coelho Rogerio Vivaldi, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, Katherine A High, Stephen W Webster and Steven Altschuler. View Institutional Ownership Trends for Spark Therapeutics.
Who sold Spark Therapeutics stock? Who is selling Spark Therapeutics stock?
Spark Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C. and Sofinnova Management VIII L.L.C.. Company insiders that have sold Spark Therapeutics stock in the last year include Anand Mehra, Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, Katherine A High and Stephen W Webster. View Insider Buying and Selling for Spark Therapeutics.
Who bought Spark Therapeutics stock? Who is buying Spark Therapeutics stock?
How do I buy Spark Therapeutics stock?
Shares of Spark Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spark Therapeutics' stock price today?
One share of Spark Therapeutics stock can currently be purchased for approximately $72.68.
MarketBeat Community Rating for Spark Therapeutics (NASDAQ ONCE)MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Spark Therapeutics (NASDAQ:ONCE) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 1 Hold Rating, 8 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.70) |
| Consensus Price Target: | $71.28 (1.93% downside) |
Analysts' Ratings History for Spark Therapeutics (NASDAQ:ONCE)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/24/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $85.00 | High |  |
| 7/24/2017 | Chardan Capital | Reiterated Rating | Hold -> Neutral | | High | |
| 7/17/2017 | Cantor Fitzgerald | Set Price Target | Buy | $94.00 | Medium | |
| 6/28/2017 | William Blair | Initiated Coverage | Outperform -> Outperform | | High | |
| 5/10/2017 | Wedbush | Reiterated Rating | Underperform | $28.00 | Medium | |
| 4/10/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $76.00 | Low | |
| 4/7/2017 | BMO Capital Markets | Reiterated Rating | Outperform | $69.00 | Low | |
| 2/22/2017 | Cowen and Company | Set Price Target | Buy | $75.00 | N/A | |
| 2/22/2017 | J P Morgan Chase & Co | Set Price Target | Buy | $82.00 | N/A | |
| 2/9/2017 | Leerink Swann | Initiated Coverage | Outperform -> Outperform | $85.00 | N/A | |
| 7/12/2016 | Royal Bank Of Canada | Initiated Coverage | Outperform | $70.00 | N/A | |
| 6/21/2016 | SunTrust Banks, Inc. | Boost Price Target | Buy | $64.00 -> $72.00 | N/A | |
| 4/12/2016 | Evercore ISI | Initiated Coverage | Buy | $37.00 | N/A | |
| 3/30/2016 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Buy -> Neutral | $44.00 | N/A | |
| 12/24/2015 | Wunderlich | Downgrade | Buy -> Hold | | N/A | |
| 10/11/2015 | Roth Capital | Reiterated Rating | Buy | | N/A | |
(Data available from 7/27/2015 forward)
Earnings History for Spark Therapeutics (NASDAQ:ONCE)Earnings History by Quarter for Spark Therapeutics (NASDAQ ONCE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/9/2017 | Q1 2017 | ($1.36) | ($1.70) | $1.35 million | $1.27 million | View | Listen | |
| 2/22/2017 | Q416 | ($1.12) | ($1.21) | $1.32 million | $16.30 million | View | Listen | |
| 11/3/2016 | Q316 | ($1.01) | ($1.07) | $1.26 million | $1.30 million | View | N/A | |
| 8/10/2016 | Q216 | ($0.97) | ($1.04) | $1.17 million | $1.29 million | View | Listen | |
| 5/4/2016 | Q116 | ($0.84) | ($0.95) | $1.48 million | $1.29 million | View | Listen | |
| 3/9/2016 | Q415 | ($0.73) | ($0.24) | $1.30 million | $17.20 million | View | Listen | |
| 11/4/2015 | Q315 | ($0.48) | ($0.70) | $4.43 million | $1.30 million | View | Listen | |
| 8/5/2015 | Q215 | ($0.13) | ($0.60) | $4.50 million | $1.29 million | View | Listen | |
| 5/6/2015 | Q115 | ($0.61) | ($0.58) | $1.20 million | $1.30 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Spark Therapeutics (NASDAQ:ONCE)2017 EPS Consensus Estimate: ($6.58)
2018 EPS Consensus Estimate: ($5.86)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 4 | ($1.75) | ($1.32) | ($1.44) |
| Q2 2017 | 5 | ($1.77) | ($1.71) | ($1.73) |
| Q3 2017 | 5 | ($1.80) | ($1.73) | ($1.76) |
| Q4 2017 | 5 | ($1.79) | ($1.18) | ($1.64) |
| Q1 2018 | 1 | ($1.67) | ($1.67) | ($1.67) |
| Q2 2018 | 1 | ($1.43) | ($1.43) | ($1.43) |
| Q3 2018 | 1 | ($1.40) | ($1.40) | ($1.40) |
| Q4 2018 | 1 | ($1.36) | ($1.36) | ($1.36) |
(Data provided by Zacks Investment Research)
Dividend History for Spark Therapeutics (NASDAQ:ONCE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Spark Therapeutics (NASDAQ:ONCE)Insider Ownership Percentage: 7.30%
Institutional Ownership Percentage: 88.94%
Insider Trades by Quarter for Spark Therapeutics (NASDAQ:ONCE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/25/2017 | Katherine A High | Insider | Sell | 10,000 | $72.53 | $725,300.00 | |
| 7/24/2017 | Anand Mehra | Director | Sell | 211,858 | $70.15 | $14,861,838.70 | |
| 7/24/2017 | Daniel Faga | Insider | Sell | 3,000 | $70.00 | $210,000.00 | |
| 7/5/2017 | Jeffrey D Marrazzo | CEO | Sell | 5,669 | $65.00 | $368,485.00 | |
| 6/29/2017 | Daniel Faga | Insider | Sell | 4,500 | $62.71 | $282,195.00 | |
| 6/27/2017 | Katherine A High | Insider | Sell | 10,000 | $60.96 | $609,600.00 | |
| 6/21/2017 | Anand Mehra | Director | Sell | 6,302 | $65.00 | $409,630.00 | |
| 6/21/2017 | Jeffrey D Marrazzo | CEO | Sell | 9,331 | $65.00 | $606,515.00 | |
| 6/19/2017 | Katherine A High | Insider | Sell | 10,000 | $60.00 | $600,000.00 | |
| 6/19/2017 | Stephen W Webster | CFO | Sell | 7,663 | $60.00 | $459,780.00 | |
| 6/7/2017 | Barge Joseph La | General Counsel | Sell | 5,000 | $55.00 | $275,000.00 | |
| 4/25/2017 | Katherine A High | Insider | Sell | 15,000 | $55.33 | $829,950.00 | |
| 4/25/2017 | Stephen W Webster | CFO | Sell | 10,000 | $55.18 | $551,800.00 | |
| 4/24/2017 | Katherine A High | Insider | Sell | 2,060 | $55.01 | $113,320.60 | |
| 4/24/2017 | Stephen W Webster | CFO | Sell | 1,898 | $55.00 | $104,390.00 | |
| 4/3/2017 | Barge Joseph La | General Counsel | Sell | 5,000 | $52.73 | $263,650.00 | |
| 3/1/2017 | Anand Mehra | Director | Sell | 84,654 | $65.02 | $5,504,203.08 | |
| 3/1/2017 | Barge Joseph La | General Counsel | Sell | 5,000 | $64.41 | $322,050.00 | |
| 2/28/2017 | Anand Mehra | Director | Sell | 25,274 | $65.02 | $1,643,315.48 | |
| 2/27/2017 | Anand Mehra | Director | Sell | 41,910 | $65.02 | $2,724,988.20 | |
| 2/16/2017 | Anand Mehra | Director | Sell | 35,347 | $65.03 | $2,298,615.41 | |
| 2/7/2017 | Anand Mehra | Director | Sell | 25,334 | $65.06 | $1,648,230.04 | |
| 12/16/2016 | Anand Mehra | Director | Sell | 349,656 | $53.46 | $18,692,609.76 | |
| 12/15/2016 | Barge Joseph La | Insider | Sell | 3,000 | $52.98 | $158,940.00 | |
| 12/13/2016 | Anand Mehra | Director | Sell | 122,532 | $55.17 | $6,760,090.44 | |
| 11/14/2016 | Katherine A High | Insider | Sell | 10,000 | $60.30 | $603,000.00 | |
| 10/17/2016 | Jeffrey D Marrazzo | CEO | Sell | 5,000 | $54.66 | $273,300.00 | |
| 10/3/2016 | Barge Joseph La | Insider | Sell | 3,000 | $60.14 | $180,420.00 | |
| 9/16/2016 | Jeffrey D Marrazzo | CEO | Sell | 10,000 | $62.68 | $626,800.00 | |
| 9/15/2016 | Katherine A High | Insider | Sell | 10,000 | $60.37 | $603,700.00 | |
| 8/16/2016 | Hospital Of Philade Children's | Director | Sell | 1,000,000 | $60.90 | $60,900,000.00 | |
| 8/11/2016 | Anand Mehra | Director | Sell | 29,963 | $60.13 | $1,801,675.19 | |
| 8/11/2016 | Jeffrey D Marrazzo | CEO | Sell | 16,970 | $60.04 | $1,018,878.80 | |
| 8/10/2016 | Katherine A High | Insider | Sell | 1,890 | $60.00 | $113,400.00 | |
| 8/8/2016 | Anand Mehra | Director | Sell | 100 | $60.47 | $6,047.00 | |
| 8/8/2016 | Jeffrey D Marrazzo | CEO | Sell | 900 | $60.24 | $54,216.00 | |
| 8/8/2016 | Katherine A High | Insider | Sell | 500 | $60.24 | $30,120.00 | |
| 8/4/2016 | Anand Mehra | Director | Sell | 5,064 | $60.00 | $303,840.00 | |
| 8/3/2016 | Jeffrey D Marrazzo | CEO | Sell | 16,530 | $60.02 | $992,130.60 | |
| 8/3/2016 | Katherine A High | Insider | Sell | 17,610 | $60.02 | $1,056,952.20 | |
| 8/1/2016 | Anand Mehra | Director | Sell | 22,665 | $60.03 | $1,360,579.95 | |
| 8/1/2016 | Jeffrey D Marrazzo | CEO | Sell | 12,348 | $60.03 | $741,250.44 | |
| 8/1/2016 | Katherine A High | Insider | Sell | 13,983 | $60.02 | $839,259.66 | |
| 7/18/2016 | Jeffrey D Marrazzo | CEO | Sell | 5,000 | $52.53 | $262,650.00 | |
| 7/15/2016 | Coelho Rogerio Vivaldi | Insider | Sell | 7,000 | $53.03 | $371,210.00 | |
| 7/5/2016 | Barge Joseph La | Insider | Sell | 3,000 | $52.24 | $156,720.00 | |
| 6/20/2016 | Hospital Of Philade Children's | Major Shareholder | Sell | 1,000,000 | $42.30 | $42,300,000.00 | |
| 6/15/2016 | Jeffrey D Marrazzo | CEO | Sell | 5,000 | $46.49 | $232,450.00 | |
| 5/31/2016 | Anand Mehra | Director | Sell | 500 | $60.00 | $30,000.00 | |
| 5/23/2016 | Katherine A High | Insider | Sell | 10,000 | $54.42 | $544,200.00 | |
| 5/20/2016 | Barge Joseph La | Insider | Sell | 10,000 | $47.65 | $476,500.00 | |
| 5/20/2016 | Stephen W Webster | CFO | Sell | 20,000 | $50.39 | $1,007,800.00 | |
| 5/19/2016 | Jeffrey D Marrazzo | CEO | Sell | 25,000 | $46.01 | $1,150,250.00 | |
| 4/21/2016 | Coelho Rogerio Vivaldi | Insider | Sell | 7,000 | $40.02 | $280,140.00 | |
| 12/28/2015 | Hospital Of Philade Children's | Major Shareholder | Sell | 131,505 | $44.18 | $5,809,890.90 | |
| 12/21/2015 | Hospital Of Philade Children's | Major Shareholder | Sell | 1,000,000 | $44.18 | $44,180,000.00 | |
| 12/1/2015 | Katherine A High | Insider | Sell | 10,000 | $55.31 | $553,100.00 | |
| 11/27/2015 | Anand Mehra | Director | Sell | 22,961 | $60.01 | $1,377,889.61 | |
| 11/16/2015 | Katherine A High | Insider | Sell | 10,000 | $53.77 | $537,700.00 | |
| 11/12/2015 | Anand Mehra | Director | Sell | 130,605 | $60.11 | $7,850,666.55 | |
| 10/14/2015 | Katherine A. High | insider | Sell | 30,000 | $49.34 | $1,480,200.00 | |
| 10/13/2015 | Katherine A. High | insider | Sell | 10,000 | $48.00 | $480,000.00 | |
| 10/12/2015 | Jeffrey D. Marrazzo | CEO | Sell | 75,000 | $48.35 | $3,626,250.00 | |
| 10/9/2015 | Jeffrey D. Marrazzo | CEO | Sell | 75,000 | $47.82 | $3,586,500.00 | |
| 10/8/2015 | Anand Mehra | Director | Sell | 529,544 | $45.46 | $24,073,070.24 | |
| 10/7/2015 | Coelho Rogerio Vivaldi | insider | Sell | 41,000 | $48.85 | $2,002,850.00 | |
| 10/7/2015 | Stephen W. Webster | CFO | Sell | 20,000 | $48.86 | $977,200.00 | |
| 10/7/2015 | Steven Altschuler | Director | Buy | 5,000 | $49.11 | $245,550.00 | |
| 2/4/2015 | Anand Mehra | Director | Buy | 225,000 | $23.00 | $5,175,000.00 | |
| 2/4/2015 | Hospital Of Philade Children's | Major Shareholder | Buy | 100,000 | $23.00 | $2,300,000.00 | |
| 2/4/2015 | Stephen W Webster | CFO | Buy | 2,500 | $23.00 | $57,500.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Spark Therapeutics (NASDAQ:ONCE)
Latest Headlines for Spark Therapeutics (NASDAQ:ONCE)
| Source: |
|
| Date | Headline |
|---|
 | Spark Therapeutics, Inc. (NASDAQ:ONCE) Insider Sells $210,000.00 in Stock
www.americanbankingnews.com - July 26 at 8:22 PM |
| Katherine A. High Sells 10,000 Shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) Stock
www.americanbankingnews.com - July 26 at 7:58 PM |
| Insider Selling: Spark Therapeutics, Inc. (ONCE) Director Sells 211,858 Shares of Stock
www.americanbankingnews.com - July 26 at 7:16 PM |
| Chardan Capital Reiterates Neutral Rating for Spark Therapeutics, Inc. (ONCE)
www.americanbankingnews.com - July 24 at 10:06 AM |
 | Spark Therapeutics (ONCE) Receives FDA Rare Pediatric Disease ... - StreetInsider.com
www.streetinsider.com - July 21 at 5:37 AM |
 | Spark Therapeutics Receives Rare Pediatric Disease Designation for Investigational LUXTURNA™ (voretigene neparvovec) from FDA
finance.yahoo.com - July 21 at 5:37 AM |
| Spark Therapeutics, Inc. (ONCE) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - July 19 at 11:08 PM |
| Brokerages Anticipate Spark Therapeutics, Inc. (ONCE) Will Announce Earnings of -$1.75 Per Share
www.americanbankingnews.com - July 17 at 2:28 PM |
 | FDA accepts for priority review Spark Therapeutics' gene therapy for blindness
www.bizjournals.com - July 17 at 11:35 AM |
| Spark Therapeutics’ Biologics License Application for Investigational Voretigene Neparvovec Accepted for Filing by FDA
finance.yahoo.com - July 17 at 11:35 AM |
| Financial Analysis: Spark Therapeutics (ONCE) & Sucampo Pharmaceuticals (SCMP)
www.americanbankingnews.com - July 16 at 12:25 PM |
| Spark Therapeutics, Inc. (ONCE) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 14 at 5:02 PM |
| Spark Therapeutics Announces Publication in The Lancet of Pivotal Phase 3 Clinical Trial Data for Investigational Voretigene Neparvovec
finance.yahoo.com - July 14 at 7:10 AM |
| Jefferies Group Weighs in on Spark Therapeutics, Inc.'s Q2 2017 Earnings (NASDAQ:ONCE)
www.americanbankingnews.com - July 13 at 8:29 AM |
| Spark Therapeutics (ONCE) Presents Updated Interim Hemophilia B Data at ISTH - StreetInsider.com
www.streetinsider.com - July 12 at 6:36 AM |
 | Implied Volatility Surging for Spark Therapeutics (ONCE) Stock Options - Nasdaq
www.nasdaq.com - July 12 at 6:36 AM |
| Implied Volatility Surging for Spark Therapeutics (ONCE) Stock Options
finance.yahoo.com - July 12 at 6:36 AM |
| Spark Therapeutics Presents Updated Interim Hemophilia B Data Supporting Consistent and Sustained Response at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress
finance.yahoo.com - July 11 at 6:20 AM |
| ETFs with exposure to Spark Therapeutics, Inc. : July 10, 2017
finance.yahoo.com - July 11 at 6:20 AM |
| Jefferies Group LLC Begins Coverage on Spark Therapeutics, Inc. (NASDAQ:ONCE)
www.americanbankingnews.com - July 10 at 5:26 PM |
| Insider Selling: Spark Therapeutics, Inc. (NASDAQ:ONCE) CEO Sells 5,669 Shares of Stock
www.americanbankingnews.com - July 7 at 8:16 PM |
| Spark Therapeutics, Inc. Forecasted to Earn Q2 2017 Earnings of ($1.73) Per Share (ONCE)
www.americanbankingnews.com - June 30 at 8:43 AM |
| Spark Therapeutics, Inc. (ONCE) Insider Katherine A. High Sells 10,000 Shares
www.americanbankingnews.com - June 29 at 7:49 PM |
| Insider Selling: Spark Therapeutics, Inc. (ONCE) Insider Sells 4,500 Shares of Stock
www.americanbankingnews.com - June 29 at 7:48 PM |
| Spark Therapeutics, Inc. (ONCE) Receives New Coverage from Analysts at William Blair
www.americanbankingnews.com - June 28 at 8:16 AM |
| Analyzing Pain Therapeutics (PTIE) and Spark Therapeutics (ONCE)
www.americanbankingnews.com - June 24 at 10:14 PM |
| $1.32 Million in Sales Expected for Spark Therapeutics, Inc. (ONCE) This Quarter
www.americanbankingnews.com - June 23 at 4:02 PM |
| Spark Therapeutics to Present Updated Hemophilia B Data at the International Society on Thrombosis and ... - Nasdaq
www.nasdaq.com - June 23 at 8:48 AM |
| Spark Therapeutics to Present Updated Hemophilia B Data at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress
finance.yahoo.com - June 23 at 8:48 AM |
| Jeffrey D. Marrazzo Sells 9,331 Shares of Spark Therapeutics, Inc. (ONCE) Stock
www.americanbankingnews.com - June 22 at 7:28 PM |
| Anand Mehra Sells 6,302 Shares of Spark Therapeutics, Inc. (ONCE) Stock
www.americanbankingnews.com - June 22 at 7:26 PM |
| BidaskClub Upgrades Spark Therapeutics, Inc. (ONCE) to Hold
www.americanbankingnews.com - June 22 at 6:43 PM |
| Katherine A. High Sells 10,000 Shares of Spark Therapeutics, Inc. (ONCE) Stock
www.americanbankingnews.com - June 21 at 7:47 PM |
| Stephen W. Webster Sells 7,663 Shares of Spark Therapeutics, Inc. (ONCE) Stock
www.americanbankingnews.com - June 21 at 7:47 PM |
| Zacks: Brokerages Anticipate Spark Therapeutics, Inc. (ONCE) to Post -$1.75 EPS
www.americanbankingnews.com - June 21 at 10:18 AM |
| Spark Therapeutics, Inc. (ONCE) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - June 20 at 11:40 PM |
| Spark Therapeutics, Inc. (ONCE) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - June 19 at 4:40 PM |
| ETFs with exposure to Spark Therapeutics, Inc. : June 15, 2017
finance.yahoo.com - June 16 at 8:32 AM |
| Spark Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ONCE-US : June 9, 2017
finance.yahoo.com - June 9 at 7:16 PM |
| Spark Therapeutics Inc (ONCE) General Counsel Sells $275,000.00 in Stock
www.americanbankingnews.com - June 8 at 7:28 PM |
 | Spark Therapeutics to Participate in Multiple Conferences in June - GlobeNewswire (press release)
globenewswire.com - June 1 at 8:46 AM |
| Spark Therapeutics to Participate in Multiple Conferences in June
finance.yahoo.com - June 1 at 8:46 AM |
| Spark Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ONCE-US : May 29, 2017
finance.yahoo.com - May 29 at 8:36 AM |
| $1.32 Million in Sales Expected for Spark Therapeutics Inc (ONCE) This Quarter
www.americanbankingnews.com - May 28 at 10:16 AM |
| Spark Therapeutics Inc (ONCE) Expected to Post Earnings of -$1.75 Per Share
www.americanbankingnews.com - May 26 at 7:37 AM |
| ETFs with exposure to Spark Therapeutics, Inc. : May 25, 2017
finance.yahoo.com - May 26 at 5:33 AM |
| ETFs with exposure to Spark Therapeutics, Inc. : May 25, 2017
finance.yahoo.com - May 26 at 5:33 AM |
| Spark Therapeutics, Inc. :ONCE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 7:15 PM |
| Spark Therapeutics Inc (ONCE) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 23 at 2:20 PM |
| Spark Therapeutics Inc (ONCE) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 21 at 8:02 PM |
Spark Therapeutics (ONCE) Chart for Thursday, July, 27, 2017
